AN AUDIT TO DETERMINE THE SAFETY OF THE NOVEL ORAL ANTICOAGULANTS, DABIGATRAN AND RIVAROXABAN, FOR PATIENTS INITIATED ON ANTICOAGULANT THERAPY

被引：0
|
作者：
Kurunadalingam, H. [1 ]
Vizcaychipi, M. P. [1 ]
Patel, S. [1 ]
Gabriel, I. H. [2 ]
Yarranton, H. [2 ]
Morgan, D. J. Richard [3 ]
机构：
[1] Chelsea & Westminster Hosp, Anaesthesia, London, England
[2] Chelsea & Westminster Hosp, Med, London, England
[3] Chelsea & Westminster Hosp, Med & Emergency Dept Directorate, London, England
来源：
ANESTHESIA AND ANALGESIA | 2014年 / 118卷
关键词：
D O I：
暂无
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
S-216
引用
收藏
页码：S216 / S216
页数：1
相关论文
共 50 条
  • [1] AN AUDIT TO DETERMINE THE SAFETY OF THE NOVEL ORAL ANTICOAGULANTS, DABIGATRAN AND RIVAROXABAN, FOR PATIENTS INITIATED ON ANTICOAGULANT THERAPY
    Kurunadalingam, H.
    Patel, S.
    Gabriel, I.
    Morgan, R.
    Yarranton, H.
    Vizcaychipi, M.
    HAEMATOLOGICA, 2014, 99 : 212 - 213
  • [2] EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN AND APIXABAN
    Elnadoury, Ola
    Yuen, Meggie
    Oh, Erin
    Abraham, Teena
    Saad, Nasser
    CRITICAL CARE MEDICINE, 2014, 42 (12)
  • [3] Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban
    Sattari, Maryam
    Lowenthal, David T.
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (04) : 332 - 338
  • [4] Laboratory monitoring of novel oral anticoagulants rivaroxaban and dabigatran
    Eerenberg, E. S.
    Kamphuisen, P. W.
    Sijpkens, M. K.
    Meijers, J. C.
    Buller, H. R.
    Levi, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 956 - 956
  • [5] Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development
    Ufer, Mike
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (03) : 572 - 585
  • [6] THROMBIN GENERATION TEST IN PATIENTS UNDER NEW ORAL ANTICOAGULANTS (DABIGATRAN AND RIVAROXABAN)
    Cabrera, N.
    Moret, A.
    Mesa, E.
    Vila, V.
    Mira, Y.
    Ferrando, F.
    Aznar, Jose A.
    Bonanad, S.
    THROMBOSIS RESEARCH, 2014, 133 : S43 - S44
  • [7] Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery
    Heard, L. Kevin
    Shanahan, Christine
    Maggio, Kurt L.
    DERMATOLOGIC SURGERY, 2017, 43 (04) : 597 - 599
  • [8] COMPARISON OF COSTS AND HEALTHCARE UTILIZATION BETWEEN PATIENTS USING NOVEL ORAL ANTICOAGULANTS (DABIGATRAN & RIVAROXABAN) VERSUS WARFARIN
    Deshpande, C. G.
    Temkin, Willey C.
    Kogut, S.
    Laforge, R.
    VALUE IN HEALTH, 2017, 20 (05) : A268 - A268
  • [9] Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery
    Chang, Timothy W.
    Arpey, Christopher J.
    Baum, Christian L.
    Brewer, Jerry D.
    Hochwalt, Phillip C.
    Hocker, Thomas L.
    Roenigk, Randall K.
    Otley, Clark C.
    DERMATOLOGIC SURGERY, 2015, 41 (07) : 784 - 793
  • [10] Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban
    Levi, Marcel
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) : 201 - 202
12345